RECOVERY Trial Data on Baricitinib in Patients Hospitalized with Coronavirus Disease 2019
Open Access
- 1 January 2022
- journal article
- research article
- Published by Touch Medical Media, Ltd. in Infectious Diseases
- Vol. 1 (1)
Abstract
Identifying drugs that control the progression of SARS-CoV-2 and its symptoms has been an urgent research priority during the coronavirus disease 2019Keywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 6 references indexed in Scilit:
- Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trialseClinicalMedicine, 2022
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialThe Lancet Respiratory Medicine, 2022
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialThe Lancet Respiratory Medicine, 2021
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19New England Journal of Medicine, 2021
- Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial findsBMJ, 2020
- Baricitinib: A Review in Rheumatoid ArthritisDrugs, 2018